WASHINGTON, May 11, 2026
The U.S. Food and Drug Administration announced a new initiative aimed at accelerating drug repurposing efforts to address significant unmet medical needs across multiple disease categories, particularly rare diseases, chronic illnesses, neurodegenerative disorders, metabolic diseases, and substance use disorders. The agency confirmed it is formally requesting public input from researchers, clinicians, patients, pharmaceutical developers, and healthcare stakeholders regarding existing FDA-approved drugs that may have potential new therapeutic applications supported by scientific evidence.
The announcement forms part of a broader FDA strategy focused on modernizing drug labeling and expanding access to treatments by leveraging existing clinical and safety data from already approved medicines. According to the agency, repurposing approved drugs for new indications or patient populations could substantially reduce development timelines while improving treatment availability for patients who currently lack effective therapeutic options. FDA officials emphasized that the initiative will prioritize therapies where scientific evidence may already support expanded use but where limited commercial incentives have slowed regulatory development efforts.
FDA Targets Unmet Medical Needs Through Drug Repurposing
The FDA stated that many approved therapies may possess untapped potential for treating diseases beyond their original indications, especially in areas where traditional drug development remains economically challenging. Agency officials explained that utilizing previously established safety profiles and clinical experience can significantly accelerate the development pathway for new treatment uses. The FDA specifically highlighted interest in disease areas associated with substantial unmet need, including rare genetic diseases, neurodegenerative disorders, women’s and men’s health conditions, chronic inflammatory diseases, and metabolic disorders.
The agency is now seeking public recommendations for approved drugs that may already have sufficient scientific evidence to justify additional investigation or regulatory consideration for expanded indications. Officials noted that drug repurposing could become especially valuable in cases where pharmaceutical companies have limited financial motivation to pursue formal labeling expansions despite promising scientific data existing in the public domain.
Advertisement
Agency Seeks Clinical, Real-World, and AI-Driven Evidence
As part of the initiative, the FDA is requesting information across several categories of scientific evidence supporting potential repurposing opportunities. The agency specifically asked stakeholders to identify approved drug candidates supported by existing clinical evidence that may warrant formal regulatory review for additional therapeutic uses. The FDA also expressed interest in drugs supported by preliminary clinical observations, including data generated from case reports, observational studies, and early-stage investigations that may justify expanded research.
Additionally, the agency highlighted growing interest in emerging technologies such as artificial intelligence and machine learning, which are increasingly being used to identify previously unknown therapeutic relationships between approved drugs and disease pathways. Regulators acknowledged that AI-driven predictive modeling may become an important tool for identifying future drug repurposing opportunities, particularly for rare diseases where traditional drug discovery efforts remain limited.
FDA Builds on Existing Labeling Modernization Programs
The new repurposing initiative builds upon several existing FDA programs designed to modernize drug labeling and ensure approved therapies reflect the latest scientific evidence. The agency referenced ongoing efforts under the MODERN Labeling Act, the Best Pharmaceuticals for Children Act, and oncology-focused initiatives such as Project Renewal, which has updated labeling for multiple cancer therapies to reflect current clinical understanding.
FDA officials also cited recommendations included in the federal government’s 2025 Make Our Children Healthy Again strategy report, which encouraged expanded collaboration between the FDA and the National Institutes of Health to improve pathways for repurposed drug approvals targeting chronic diseases. The agency stated that information collected through the newly opened public docket will help guide future collaborations with federal healthcare organizations, including the NIH and Centers for Medicare and Medicaid Services, while shaping future regulatory approaches to drug repurposing and labeling modernization.
Source: FDA press release
